Abstract 3462
Background
Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC). We tested if TKI induction followed by an early switch to NIVO improved outcome in mRCC.
Methods
Key inclusion criteria were measurable advanced or metastatic ccRCC, ECOG PS 0-2, adequate organ function, and PR or SD after sunitinib (50 mg, 4-2 regime) or pazopanib (800 mg OD) for 10-12 weeks. 1:1 randomized to either continue TKI treatment or receive nivolumab 240 or 480 mg IV q2-4wks, until PD or intolerance. Imaging occurred q12wks and health-related quality of life (HR-QoL) was assessed monthly x3 and q12wks thereafter (FKSI-15). Primary and key secondary endpoints were survival rate at 2 years and ORR, respectively. The trial stopped prematurely for low accrual after 49 of 244 patients were randomized.
Results
25 and 24 pts. were randomized to receive NIVO or TKI continuation, respectively. Median age was 65 years (range: 35-79), 40 pts. (82%) were male and 2 pts. (4%) had an ECOG PS of 2. MSKCC risk categories: favorable, intermediate, poor were (n; %): 15 (31), 32 (65) and 2 (4). Pazopanib was used in 22 (45). Response to TKI induction was PR in 29 (59) and SD in 20 (41). In the ITT population, best overall response rate measured from start of induction therapy was not significantly different for NIVO vs. TKI (64 vs. 70%, P = 0.76). However, when measured from time of randomization, ORR for NIVO vs. TKI was 16 vs. 48% (P = 0.029). Adverse events (AE) for NIVO vs. TKI occurred in 96% vs. 100% (all grades) and 44% vs. 67% (grades 3-5), respectively. Serious AE (SAE) for NIVO vs. TKI continuation were reported in 10 (40) and 9 (38), respectively.Table:
959P Best overall response to nivolumab or TKI treatment (ITT population)
From start of TKI induction | From randomization | |||||
---|---|---|---|---|---|---|
Category | NIVO | TKI | Total | NIVO | TKI | Total |
n | 25 | 23 | 48 | 25 | 23 | 48 |
CR | -- | 1 (4%) | 1 (2%) | -- | 1 (4%) | 1 (2%) |
PR | 16 (64%) | 15 (65%) | 31 (65%) | 4 (16%) | 10 (43%) | 14 (29) |
SD | 9 (36%) | 7 (30%) | 16 (33%) | 6 (24%) | 7 (30%) | 13 (27%) |
PD | -- | -- | -- | 11 (44%) | 3 (13%) | 14 (29%) |
NE | -- | -- | -- | 4 (16%) | 2 (9%) | 6 (12%) |
Conclusions
TKI induction followed by early switch to NIVO did not improve ORR in patients responsive to TKI. These results do not support the notion that TKI pretreatment sensitizes for nivolumab efficacy. Major limitations of our trial are the premature closure and the limited sample size.
Clinical trial identification
2016-002170-13; NCT02959554.
Editorial acknowledgement
Legal entity responsible for the study
AIO-Studien-gGmbH, Berlin.
Funding
Bristol-Myers Squibb.
Disclosure
V. Grünwald: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Shareholder / Stockholder / Stock options: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Ipsen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Eisai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Novartis; Research grant / Funding (self): Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Shareholder / Stockholder / Stock options: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Cerulean; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Shareholder / Stockholder / Stock options: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Art tempi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony: COCS; Advisory / Consultancy, Speaker Bureau / Expert testimony: ClinSol; Advisory / Consultancy, Speaker Bureau / Expert testimony: EUSAPharm; Advisory / Consultancy, Speaker Bureau / Expert testimony: MedUpdate; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Serono; Advisory / Consultancy, Speaker Bureau / Expert testimony: MedKomAkademie; Advisory / Consultancy, Speaker Bureau / Expert testimony: NewConceptOncology; Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Johnson & Johnson; Advisory / Consultancy, Speaker Bureau / Expert testimony: PharmaMar; Advisory / Consultancy, Speaker Bureau / Expert testimony: PeerVoice; Advisory / Consultancy, Speaker Bureau / Expert testimony: StreamedUp!; Advisory / Consultancy, Speaker Bureau / Expert testimony: ThinkWired!. All other authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract